Alchemab Therapeutics is focusing on protective immune responses associated with individuals who have shown resistance to a disease. It is “looking at nature’s solution to potential diseases,” CEO Alex Leech told In Vivo.
The biotech is identifying “novel and unbiased” therapeutics by evaluating convergent antibody responses using a variety of analytical tools, particularly...